Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

NCT02254018 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Neoplasms

Interventions

DRUG: bivatuzumab mertansine

Sponsor

Boehringer Ingelheim